AU1615492A - Rapamycin metabolites - Google Patents

Rapamycin metabolites

Info

Publication number
AU1615492A
AU1615492A AU16154/92A AU1615492A AU1615492A AU 1615492 A AU1615492 A AU 1615492A AU 16154/92 A AU16154/92 A AU 16154/92A AU 1615492 A AU1615492 A AU 1615492A AU 1615492 A AU1615492 A AU 1615492A
Authority
AU
Australia
Prior art keywords
mass
charge ratio
rapamycin
virtue
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU16154/92A
Other versions
AU659452B2 (en
Inventor
Uwe Christians
Martin Sattler
Karl Friedrich Sewing
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of AU1615492A publication Critical patent/AU1615492A/en
Application granted granted Critical
Publication of AU659452B2 publication Critical patent/AU659452B2/en
Assigned to WYETH reassignment WYETH Request to Amend Deed and Register Assignors: AMERICAN HOME PRODUCTS CORPORATION
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention provides metabolites of rapamycin, the first of which is 41-O-desmethyl rapamycin, having a deprotonated molecular ion detected at a mass to charge ratio of 899, and a characteristic desorption chemical ionization mass spectroscopic fragmentation pattern comprising ions detected at a mass to charge ratio of 591, 569, 559, 543, 529, 421, and 308. A second compound of this invention is a hydroxylated metabolite of rapamycin having a deprotonated molecular ion detected at a mass to charge ratio of 928, and a characteristic direct chemical ionization mass spectroscopic fragmentation pattern comprising ions detected at a mass to charge ratio of 607, 571, 545, 513, 322, 290, and 241 amu. The compounds of this invention, by virtue of their immunosuppressive activity are useful in treating transplantation rejection, host vs. graft disease, autoimmune diseases and diseases of inflammation; by virtue of their antitumor activity are useful in treating solid tumors; and by virtue of their antifungal activity are useful in treating fungal infections.
AU16154/92A 1991-05-14 1992-05-11 Rapamycin metabolites Ceased AU659452B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/699,505 US5776943A (en) 1991-05-14 1991-05-14 Rapamycin metabolites
US699505 1991-05-14

Publications (2)

Publication Number Publication Date
AU1615492A true AU1615492A (en) 1992-11-19
AU659452B2 AU659452B2 (en) 1995-05-18

Family

ID=24809620

Family Applications (1)

Application Number Title Priority Date Filing Date
AU16154/92A Ceased AU659452B2 (en) 1991-05-14 1992-05-11 Rapamycin metabolites

Country Status (13)

Country Link
US (1) US5776943A (en)
EP (1) EP0514144B1 (en)
JP (1) JP3183554B2 (en)
KR (1) KR920021552A (en)
AT (1) ATE174918T1 (en)
AU (1) AU659452B2 (en)
CA (1) CA2068349C (en)
DE (1) DE69227942T2 (en)
DK (1) DK0514144T3 (en)
ES (1) ES2126586T3 (en)
GR (1) GR3029767T3 (en)
HK (1) HK1010369A1 (en)
IE (1) IE921525A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9302569D0 (en) * 1993-02-10 1993-03-24 Smithkline Beecham Plc Novel compound
GB9315914D0 (en) * 1993-07-31 1993-09-15 Smithkline Beecham Plc Novel compound
WO1996006847A1 (en) * 1994-08-31 1996-03-07 Pfizer Inc. Process for preparing demethylrapamycins
US5922730A (en) * 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
IT1289815B1 (en) * 1996-12-30 1998-10-16 Sorin Biomedica Cardio Spa ANGIOPLASTIC STENT AND RELATED PRODUCTION PROCESS
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
DE602004018927D1 (en) * 2003-06-18 2009-02-26 Genelux Corp MODIFIED RECOMBINANT VACCINIA VIRUSES, USES THEREOF
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
CN115825296A (en) * 2022-10-13 2023-03-21 中生北控生物科技股份有限公司 Sample pretreatment kit and treatment method for tacrolimus detection in blood sample

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) * 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US4316885A (en) * 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US4650803A (en) * 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US4981792A (en) * 1988-06-29 1991-01-01 Merck & Co., Inc. Immunosuppressant compound
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
EP0413532A3 (en) * 1989-08-18 1991-05-15 Fisons Plc Macrocyclic compounds
US5023264A (en) * 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
US5023263A (en) * 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
US5023262A (en) * 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
FI921595A (en) * 1991-04-17 1992-10-18 American Home Prod RAPAMYCINKARBAMATER
US5091389A (en) * 1991-04-23 1992-02-25 Merck & Co., Inc. Lipophilic macrolide useful as an immunosuppressant
US5102876A (en) * 1991-05-07 1992-04-07 American Home Products Corporation Reduction products of rapamycin
JP3108192B2 (en) * 1991-05-07 2000-11-13 アメリカン・ホーム・プロダクツ・コーポレイション Reduction products of rapamycin for immunosuppressive, anti-inflammatory or antifungal agents

Also Published As

Publication number Publication date
DE69227942D1 (en) 1999-02-04
ES2126586T3 (en) 1999-04-01
KR920021552A (en) 1992-12-18
IE921525A1 (en) 1992-11-18
AU659452B2 (en) 1995-05-18
DE69227942T2 (en) 1999-08-26
HK1010369A1 (en) 1999-06-17
JP3183554B2 (en) 2001-07-09
ATE174918T1 (en) 1999-01-15
EP0514144B1 (en) 1998-12-23
US5776943A (en) 1998-07-07
CA2068349C (en) 2002-04-09
GR3029767T3 (en) 1999-06-30
DK0514144T3 (en) 1999-08-23
EP0514144A2 (en) 1992-11-19
EP0514144A3 (en) 1993-03-03
JPH05130884A (en) 1993-05-28
CA2068349A1 (en) 1992-11-15

Similar Documents

Publication Publication Date Title
AU1615492A (en) Rapamycin metabolites
AU4149797A (en) Multipole ion guide ion trap mass spectrometry
AU7515996A (en) Miniature quadrupole mass spectrometer array
AU4059597A (en) Ion storage time-of-flight mass spectrometer
WO1998056023A3 (en) Miniature micromachined quadrupole mass spectrometer array and method of making the same
AU1932095A (en) Multipole ion guide for mass spectrometry
EP1884980B8 (en) Mass spectrometer
CA2373351A1 (en) Ion mobility and mass spectrometer
CA2067541A1 (en) Reduction products of rapamycin
CA2114262A1 (en) Ion trap mass spectrometer method and apparatus for improved sensitivity
EP0459602A3 (en) Mass spectrometric high-frequency quadrupole cage with superposed multipole fields
GB2315592B (en) Introduction of ions from ion sources into mass spectrometers
GB2280305B (en) Quadrupole ion trap
CA2199664A1 (en) Novel prodrugs for the therapy of tumors and inflammatory disorders
AU5516399A (en) Dihydro-(1,2,3)triazolo-(4,5-d)pyrimidin-7-one
AU3638093A (en) Sample nebulizer and evaporation chamber for ICP and MIP emission or mass spectrometry and spectrometers comprising the same
AU3668599A (en) Ion trap mass spectrometer with electrospray ionization
CA2101156A1 (en) Chemical Ionization Mass Spectrometry Method Using Notch Filter
EP0581600A3 (en) Method of operating a quadrupole ion trap at high sensitivity.
AU3569697A (en) Method for injection of externally produced ions into a quadrupole ion trap
RS49746B (en) A substituted triazolo-pyridazine derivative, pharmaceutical composition made there from
DE69402513D1 (en) Quadrupole mass spectrometer
CA2115605A1 (en) Differential Virtual Ground Beam Blanker
EP0627436A4 (en) Carcinostatic compound and production thereof.
CA2189483A1 (en) Surface coating to improve performance of ion trap mass spectrometers

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: WYETH

Free format text: FORMER NAME WAS: AMERICAN HOME PRODUCTS CORPORATION